Non–Small-Cell Lung Cancer
Specialty Channel

Featured Article
Sotorasib therapy demonstrated durable efficacy with manageable safety for previously treated KRAS p.G12C-mutated NSCLC.
Findings from the ALTA trials show that brigatinib is effective, with manageable safety, in patients with crizotinib-refractory ALK+ NSCLC.
Second- and third-generation ALK inhibitors showed improved survival over first-generation in patients with NSCLC and brain metastases.
The FDA has granted accelerated approval to Sotorasib for adult patients with KRAS G12C mutated locally advanced or metastatic NSCLC.
According to the final J-ALEX OS analysis results, alectinib yielded no advantage in OS compared with crizotinib in patients with ALK+ NSCLC.
The most common adverse events associated with atezolizumab use in the open-label, multi-center, international IMpower110 trial include:
Tislelizumab plus chemotherapy, as a first-line treatment, showed improvement of PFS and OS in patients with advanced squamous NSCLC.
KEYNOTE‑189 study results revealed the addition of pembrolizumab to _______ improves both survival and progression free survival in metastatic NSCLC, irrespective of the tumor PD‑L1 expression.
Researchers combining selpercatinib with crizotinib were able to target MET-amplified resistance among patients with RET+ NSCLC treated with selpercatinib alone.

News

Sotorasib therapy demonstrated durable efficacy with manageable safety for previously treated KRAS p.G12C-mutated NSCLC.
Findings from the ALTA trials show that brigatinib is effective, with manageable safety, in patients with crizotinib-refractory ALK+ NSCLC.
Second- and third-generation ALK inhibitors showed improved survival over first-generation in patients with NSCLC and brain metastases.
The FDA has granted accelerated approval to Sotorasib for adult patients with KRAS G12C mutated locally advanced or metastatic NSCLC.

Interactive Features

The most common adverse events associated with atezolizumab use in the open-label, multi-center, international IMpower110 trial include:
KEYNOTE‑189 study results revealed the addition of pembrolizumab to _______ improves both survival and progression free survival in metastatic NSCLC, irrespective of the tumor PD‑L1 expression.
Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?
True or false: Platinum-based chemotherapy demonstrated a longer overall survival than atezolizumab in NSCLC patients with high PD-L1 expression.
Stay in the know.
OncNet Newsletter